Clinical Trial Update: Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating diclofenac in patients with metastatic non-small cell lung cancer who are receiving single-agent immunotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Diclofenac (diclofenac)

Snippet

Sponsor: Emory University | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING